Veterinary versus human use under Article 3(d): CJEU asked to revisit Santen By Dr Rose Hughes on Saturday, January 17, 2026 article 3(a) patents pharmaceutical patents Rose Hughes Santen SPC supplementary protection certificates +
UK takes uncompromising approach to interpretation of "the product" under Art. 3(a) SPC Regulation (Newron v Comptroller [2023] EWHC 1471) By Dr Rose Hughes on Monday, September 04, 2023 article 3(a) Brexit patents pharmaceutical patents Rose Hughes Santen SPC supplementary protection certificates +
Sweden gets into the Article 3 SPC referral game in AstraZeneca dapagliflozin case By Henry P Yang on Wednesday, March 01, 2023 article 3(a) article 3(c) patents royalty pharma SPC supplementary protection certificates Sweden Teva +
New SPC referral to the CJEU on the interpretation of Art 3(a) and (c) for combination products (Merck v Clonmel) By Dr Rose Hughes on Monday, March 07, 2022 article 3(a) article 3(c) patents Rose Hughes royalty pharma SPC supplementary protection certificates +
The SPC alphabet: Are combination product SPCs precluded by Article 3(a), (c) and/or (d)? By Dr Rose Hughes on Monday, December 13, 2021 article 3(a) article 3(c) Article 3(d) patents Rose Hughes royalty pharma Santen SPC supplementary protection certificates +
BREAKING: Court of Appeal frames Article 3(a) test as one of "claim requirement", but still upholds Truvada SPC invalidity By Annsley Merelle Ward on Thursday, December 19, 2019 #IPKat Actavis v Boehringer AG Opinion article 3(a) CJEU Court of Appeal Lilly v HGS Lord Justice Arnold lord justice floyd medeva regulatory approval SPC regulation Teva Teva v Gilead +
Article 3(a) just keeps on giving: AG Opinion in SPC referrals C-650/17 and C-114/18 By Dr Rose Hughes on Friday, September 13, 2019 article 3(a) C-650/17 C‑114/18 CJEU referral patents Regulation (EC) No. 469/2009 Rose Hughes sitgliptin SPC Truvada +